Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 396-405, 2008. First published December 18, 2007; 10.1373/clinchem.2007.093419
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow HTML Page - index.htslp
Right arrow All Versions of this Article:
clinchem.2007.093419v1
54/2/396    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Wright, C.
Right arrow Articles by Fare, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, C.
Right arrow Articles by Fare, T.
(Clinical Chemistry. 2008;54:396-405.)
© 2008 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

Characterization of Globin RNA Interference in Gene Expression Profiling of Whole-Blood Samples

Christopher Wright1, Donald Bergstrom2, Hongyue Dai1, Matthew Marton1, Mark Morris1, George Tokiwa1, Yanqun Wang1 and Thomas Fare1,a

1 Rosetta Inpharmatics, Merck & Co., Inc., Seattle, WA; 2 Merck Research Laboratories, Upper Gwynedd, PA.

aAddress correspondence to this author at: Rosetta Inpharmatics, Merck & Co., Inc., 401 Terry Ave. N., Seattle, WA 98109. Fax 206-802-6501; e-mail thomas_fare{at}merck.com.

Background: Blood-based biomarker discovery with gene expression profiling has been hampered by interference from endogenous, highly abundant {alpha}- and β-globin transcripts. We describe a means to quantify the interference of globin transcripts on profiling and the effectiveness of globin transcript mitigation by (a) defining and characterizing globin interference, (b) reproducing globin interference with synthetic transcripts, and (c) using ROC curves to measure sensitivity and specificity for a protocol for removing {alpha}- and β-globin transcripts.

Methods: We collected blood at 2 sites and extracted total RNA in PreAnalytiX PAXgene tubes. As a reference for characterizing interference, we supplemented aliquots of total RNA with synthesized globin transcripts and total RNA from human brain. Selected aliquots were processed with Ambion GLOBINclear to remove globin transcripts. All aliquots were labeled and hybridized to Agilent DNA microarrays by means of pooling schemes designed to quantify the mitigation of globin interference and to titrate gene expression signatures. Quantitative reverse transcription–PCR data were generated for comparison with microarray results.

Results: Our supplementation and pooling strategy for comparing the microarray data among samples demonstrated that mitigation could reduce an interference signature of >1000 genes to approximately 200. Analysis of samples of endogenous globin transcripts supplemented with brain RNA indicated that results obtained with the GLOBINclear treatment approach those of peripheral blood mononuclear cell preparations.

Conclusion: We confirmed that both the absolute concentrations of globin transcripts and differences in transcript concentrations within a sample set are factors that cause globin interference (Genes Immun 2005;6:588–95). The methods and transcripts we have developed may be useful for quantitatively characterizing globin mRNA interference and its mitigation.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.